3-(3-氯苄氧基)吡啶-2-胺 | 107229-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(3-氯苄氧基)吡啶-2-胺
• 英文名称: 3-(3-chlorobenzyloxy)pyridin-2-amine
• 英文别名: 2-amino-3-(3-chlorobenzyloxy)pyridine；3-[(3-Chlorophenyl)methoxy]pyridin-2-amine
• CAS: 107229-62-9
• 化学式: C₁₂H₁₁ClN₂O
• mdl: MFCD11195108
• 分子量: 234.685
• InChiKey: FHXFIGNXAAISEC-UHFFFAOYSA-N

物化性质

• 熔点：
  87.5-89 °C
• 沸点：
  390.4±32.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-氯苄氧基)吡啶-2-胺 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 38.0h， 生成 1-(3-(3-chlorobenzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea
  参考文献：
  名称：

  Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction

  摘要：

  Herein, we report a new series of aliphatic substituted pyridyl-urea small molecules synthesized as potential modulators for amyloid beta (A beta) induced mitochondrial dysfunction. Their blocking activities against A beta-induced mitochondrial permeability transition pore (mPTP) opening were evaluated by JC-1 assay which measures the change of mitochondrial membrane potential (Delta Psi m). The inhibitory activity of sixteen compounds against A beta-induced mPTP opening was superior or almost similar to that of the standard Cyclosporin A (CsA). Among them, 1-(3-(benzyloxy) pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea (5x) effectively maintained mitochondrial function and cell viabilities on ATP assay, MTT assay, and ROS assay. Using CDocker algorithm, a molecular docking model presented a plausible binding mode for 5x with cyclophilin D (CypD) receptor as a major component of mPTP. Moreover, hERG and BBB-PAMPA assays presented safe cardiotoxicity and high CNS bioavailability profiles for 5x. Taken as a whole, this report presents compound 5x as a new nonpeptidyl mPTP blocker may hold a promise for further development of Alzheimer's disease (AD) therapeutics. (C) 2016 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2016.12.057
• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 、 3-氯苄溴 在 四丁基溴化铵 、 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 18.25h， 生成 3-(3-氯苄氧基)吡啶-2-胺
  参考文献：
  名称：

  合成和评估2-（3-芳基脲基）吡啶和2-（3-芳基脲基）吡嗪作为Aβ诱导的阿尔茨海默氏病线粒体功能障碍的潜在调节剂

  摘要：

  合成了一系列的2-（3-芳基脲基）吡啶和2-（3-苄基脲基）吡啶，并将其评估为淀粉样β（Aβ）诱导的阿尔茨海默氏病（AD）中的线粒体功能障碍的潜在调节剂。通过测量线粒体膜电位（ΔΨm）变化的JC-1分析评估了41个小分子对Aβ诱导的线粒体通透性转变孔（mPTP）开口的阻断活性。25种化合物对Aβ诱导的mPTP开放的抑制活性优于标准环孢菌素A（CsA）。就线粒体和细胞安全性而言，已鉴定出六种命中化合物可能是安全的，并对其对Aβ诱导的ATP产生的恶化和细胞毒性的保护作用进行了评估。其中，化合物7fb已被鉴定为保护神经元细胞免受67％的神经细胞毒性和43％的5μM浓度的Aβ诱导的线粒体ATP抑制抑制的先导化合物。使用CDocker算法，分子对接模型以亲环蛋白D（CypD）受体作为mPTP的主要成分，为这些化合物提供了一种可能的结合模式。因此，本报告提出化合物7fb作为一种新的非肽基mPTP阻断剂

  DOI：

  10.1016/j.ejmech.2017.12.045

文献信息

• Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity
  作者：Jung-eun Park、Ahmed Elkamhawy、Ahmed H.E. Hassan、Ae Nim Pae、Jiyoun Lee、Sora Paik、Beoung-Geon Park、Eun Joo Roh

  DOI：10.1016/j.ejmech.2017.09.043

  日期：2017.12

  Herein, we report synthesis and evaluation of new twenty six small molecules against β amyloid (Aβ)-induced opening of mitochondrial permeability transition pore (mPTP) using JC-1 assay which measures the change of mitochondrial membrane potential (ΔΨm). The neuroprotective effect of seventeen compounds against Aβ-induced mPTP opening was superior to that of the standard Cyclosporin A (CsA). Fifteen

  在本文中，我们报告了使用JC-1测定法合成新的26个小分子，这些小分子针对β淀粉样蛋白（Aβ）诱导的线粒体通透性转换孔（mPTP）的打开，该方法可测量线粒体膜电位（ΔΨm）的变化。17种化合物对Aβ诱导的mPTP开放的神经保护作用优于标准环孢菌素A（CsA）。评价了十五种引发绿色至红色荧光百分比增加小于40.0％的衍生物对ATP产生，细胞活力和针对Aβ诱导的神经元细胞死亡的神经保护作用的影响。在评估的化合物中，衍生物9w，9r和9k关于ATP的产生和细胞活力具有安全性。此外，它们表现出显着的神经保护作用（分别为69.3％，51.8和48.2％）。使用CDocker算法进行的分子建模研究预测了可能的结合模式，从而解释了所引起的mPTP阻断活性。因此，这项研究表明化合物9w，9r和9k作为进一步开发针对阿尔茨海默氏病的新疗法的先导。
• [EN] RAF KINASE INHIBITORS<br/>[FR] INHIBITEURS DE RAF KINASE
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2005002673A1

  公开（公告）日：2005-01-13

  The use of a compound of the formula I or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for use in the treatment of a condition ameliorated by the inhibition of raf kinase, wherein: -X=Y- is selected from -CR2=CR3- and -CR2=N-; R1 is selected from H, halo, NRR', NHC (=O)R, NHC (=O)NRR', NH2SO2R, and C (=O)NRR', where R and R' are independently selected from H and C1-4 alkyl, and are optionally substituted by OH, NH2, SO2-NH2, C5-20 carboaryl, C5-20 heteroaryl and C3-20 heterocyclyl, or may together form, with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing C5-7 heterocyclyl group; R2 and R3 (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R4 an optionally substituted C5-20 carboaryl or C5-20 heteroaryl group; and R5 is selected from R5', halo, NHR5', C(=O)NHR5', OR5', SR5', NHC (=O)R5', NHC (=O)NHR5', NHS (=O) 2R5', wherein R5' is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH).

  使用公式I的化合物或其药学上可接受的盐或溶剂制造药物，用于治疗通过抑制Raf激酶改善的疾病，其中：-X=Y-选择自-CR2=CR3-和-CR2=N-；R1选择自H、卤素、NRR'、NHC(=O)R、NHC(=O)NRR'、NH2SO2R和C(=O)NRR'，其中R和R'独立选择自H和C1-4烷基，可选择性地被OH、NH2、SO2-NH2、C5-20碳基芳基、C5-20杂环芳基和C3-20杂环基取代，或者与它们附着的氮原子一起形成一个可选择性地被取代的含氮C5-7杂环基；R2和R3（存在时）独立选择自H、可选择性地被取代的C1-7烷基、可选择性地被取代的C5-20芳基、可选择性地被取代的C3-20杂环基、卤素、氨基、酰胺、羟基、醚、硫、硫醚、酰胺基、脲基和磺酰氨基；R4为可选择性地被取代的C5-20碳基芳基或C5-20杂环芳基；R5选择自R5'、卤素、NHR5'、C(=O)NHR5'、OR5'、SR5'、NHC(=O)R5'、NHC(=O)NHR5'和NHS(=O)2R5'，其中R5'为H或C1-3烷基（可选择性地被卤素、NH2、OH、SH取代）。
• 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
  申请人：Murray William Christopher

  公开号：US20060063782A1

  公开（公告）日：2006-03-23

  Compounds of the formula (I), wherein: —X═Y— is selected from —CR<2>=CR<3>— and —CR<2>═N—; R<1> is selected from H, halo, NRR′, NHC(═O)R, NHC(═O)NRR′, NH2SO2R, and C(═O)NRR′; R<2> and R<3> (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R<4> is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R<5> is selected from R<5′>, halo, NHR<5′>, C(═O)NHR<5′>, OR<5′>, SR<5′>, NHC(═O)R<5′>, NHC(═O)NHR<5′>, NHS(═O)R<5′>, wherein R<5′> is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.

  公式（I）的化合物，其中：—X═Y—选自—CR<2>=CR<3>—和—CR<2>═N—；R<1>选自H，卤素，NRR'，NHC(═O)R，NHC(═O)NRR'，NH2SO2R和C(═O)NRR'；R<2>和R<3>（如存在）独立地选自H，可选取代的C1-7烷基，可选取代的C5-20芳基，可选取代的C3-20杂环基，卤素，氨基，酰胺，羟基，醚，硫醚，酰胺基，尿素基和磺酰氨基；R<4>为可选取代的C5-20芳基或C5-20杂芳基；R<5>选自R<5'>，卤素，NHR<5'>，C(═O)NHR<5'>，OR<5'>，SR<5'>，NHC(═O)R<5'>，NHC(═O)NHR<5'>，NHS(═O)R<5'>，其中R<5'>为H或C1-3烷基（可选取代为卤素，NH2，OH，SH），用于治疗和治疗通过抑制p38 MAP激酶改善的疾病。
• HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：KORI Masakuni

  公开号：US20120077799A1

  公开（公告）日：2012-03-29

  Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

  提供的化合物由公式(I)表示，其中每个符号如规范中所定义，或其盐，具有AMPA（α-氨基-3-羟基-5-甲基-4-异唑烷丙酸）受体增强作用。本发明的化合物可用作预防或治疗抑郁症、精神分裂症、阿尔茨海默病或注意力缺陷多动障碍（ADHD）等疾病的药物。
• Heterocyclic compound and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08778934B2

  公开（公告）日：2014-07-15

  Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

  提供的化合物由公式（I）表示，其中每个符号如规范中所定义，或其盐，具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体潜在作用。本发明的化合物可用作预防或治疗抑郁症，精神分裂症，阿尔茨海默病或注意力缺陷多动障碍（ADHD）等药物。